This oncology project targets an undisclosed protein family. The project aims to develop pharmaceuticals directed against a family of proteins involved in the cell’s response to DNA damage (DNA damage response, DDR), cell cycle control, lysosome metabolism, and inflammatory signaling. Elevated levels of this protein family exist in a variety of cancers and correlate to poor survival in patients with cancer in, for example, liver, kidney, and pancreas. Among the possible treatments that can be developed based on this project, we see for instance combination with other treatments that inhibit the DDR, or in combination with radiation therapy. There are also potential synergies with different immunotherapy therapies.